vs

Side-by-side financial comparison of GoPro, Inc. (GPRO) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $201.7M, roughly 1.0× GoPro, Inc.). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 0.4%). GoPro, Inc. produced more free cash flow last quarter ($15.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 13.9%).

GoPro, Inc. is an American technology company founded in 2002 by Nick Woodman. It manufactures action cameras and develops its own mobile apps and video-editing software. Founded as Woodman Labs, Inc, the company is based in San Mateo, California.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

GPRO vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.0× larger
RARE
$207.3M
$201.7M
GPRO
Growing faster (revenue YoY)
RARE
RARE
+25.5% gap
RARE
25.9%
0.4%
GPRO
More free cash flow
GPRO
GPRO
$115.7M more FCF
GPRO
$15.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
13.9%
GPRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GPRO
GPRO
RARE
RARE
Revenue
$201.7M
$207.3M
Net Profit
$-128.6M
Gross Margin
31.8%
Operating Margin
-4.1%
-54.7%
Net Margin
-62.0%
Revenue YoY
0.4%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-0.06
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPRO
GPRO
RARE
RARE
Q4 25
$201.7M
$207.3M
Q3 25
$162.9M
$159.9M
Q2 25
$152.6M
$166.5M
Q1 25
$134.3M
$139.3M
Q4 24
$200.9M
$164.6M
Q3 24
$258.9M
$139.5M
Q2 24
$186.2M
$147.0M
Q1 24
$155.5M
$108.8M
Net Profit
GPRO
GPRO
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-21.3M
$-180.4M
Q2 25
$-16.4M
$-115.0M
Q1 25
$-46.7M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-8.2M
$-133.5M
Q2 24
$-47.8M
$-131.6M
Q1 24
$-339.1M
$-170.7M
Gross Margin
GPRO
GPRO
RARE
RARE
Q4 25
31.8%
Q3 25
35.1%
Q2 25
35.8%
Q1 25
32.1%
Q4 24
34.7%
Q3 24
35.5%
Q2 24
30.5%
Q1 24
34.1%
Operating Margin
GPRO
GPRO
RARE
RARE
Q4 25
-4.1%
-54.7%
Q3 25
-9.8%
-106.9%
Q2 25
-9.2%
-64.8%
Q1 25
-33.7%
-102.6%
Q4 24
-19.5%
-74.3%
Q3 24
-3.1%
-94.6%
Q2 24
-25.0%
-79.1%
Q1 24
-26.6%
-151.9%
Net Margin
GPRO
GPRO
RARE
RARE
Q4 25
-62.0%
Q3 25
-13.0%
-112.8%
Q2 25
-10.8%
-69.0%
Q1 25
-34.8%
-108.5%
Q4 24
-80.9%
Q3 24
-3.2%
-95.7%
Q2 24
-25.7%
-89.5%
Q1 24
-218.1%
-156.8%
EPS (diluted)
GPRO
GPRO
RARE
RARE
Q4 25
$-0.06
$-1.28
Q3 25
$-0.13
$-1.81
Q2 25
$-0.10
$-1.17
Q1 25
$-0.30
$-1.57
Q4 24
$-0.22
$-1.34
Q3 24
$-0.05
$-1.40
Q2 24
$-0.31
$-1.52
Q1 24
$-2.24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPRO
GPRO
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$49.7M
$421.0M
Total DebtLower is stronger
$44.3M
Stockholders' EquityBook value
$76.5M
$-80.0M
Total Assets
$428.0M
$1.5B
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPRO
GPRO
RARE
RARE
Q4 25
$49.7M
$421.0M
Q3 25
$152.8M
$202.5M
Q2 25
$58.6M
$176.3M
Q1 25
$69.6M
$127.1M
Q4 24
$102.8M
$174.0M
Q3 24
$130.2M
$150.6M
Q2 24
$133.0M
$480.7M
Q1 24
$133.7M
$112.3M
Total Debt
GPRO
GPRO
RARE
RARE
Q4 25
$44.3M
Q3 25
$43.9M
Q2 25
Q1 25
Q4 24
$0
Q3 24
$93.1M
Q2 24
$92.9M
Q1 24
$92.7M
Stockholders' Equity
GPRO
GPRO
RARE
RARE
Q4 25
$76.5M
$-80.0M
Q3 25
$80.5M
$9.2M
Q2 25
$97.9M
$151.3M
Q1 25
$110.0M
$144.2M
Q4 24
$151.7M
$255.0M
Q3 24
$183.9M
$346.8M
Q2 24
$184.7M
$432.4M
Q1 24
$224.9M
$140.3M
Total Assets
GPRO
GPRO
RARE
RARE
Q4 25
$428.0M
$1.5B
Q3 25
$538.6M
$1.2B
Q2 25
$439.0M
$1.3B
Q1 25
$462.5M
$1.3B
Q4 24
$543.7M
$1.5B
Q3 24
$661.6M
$1.5B
Q2 24
$556.8M
$1.6B
Q1 24
$575.8M
$1.3B
Debt / Equity
GPRO
GPRO
RARE
RARE
Q4 25
0.58×
Q3 25
0.55×
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.51×
Q2 24
0.50×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPRO
GPRO
RARE
RARE
Operating Cash FlowLast quarter
$15.6M
$-99.8M
Free Cash FlowOCF − Capex
$15.0M
$-100.8M
FCF MarginFCF / Revenue
7.4%
-48.6%
Capex IntensityCapex / Revenue
0.3%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-24.0M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPRO
GPRO
RARE
RARE
Q4 25
$15.6M
$-99.8M
Q3 25
$12.2M
$-91.4M
Q2 25
$8.8M
$-108.3M
Q1 25
$-57.2M
$-166.5M
Q4 24
$-25.1M
$-79.3M
Q3 24
$-2.2M
$-67.0M
Q2 24
$605.0K
$-77.0M
Q1 24
$-98.4M
$-190.7M
Free Cash Flow
GPRO
GPRO
RARE
RARE
Q4 25
$15.0M
$-100.8M
Q3 25
$11.2M
$-92.7M
Q2 25
$8.3M
$-110.7M
Q1 25
$-58.5M
$-167.8M
Q4 24
$-25.5M
$-79.5M
Q3 24
$-4.2M
$-68.6M
Q2 24
$-111.0K
$-79.0M
Q1 24
$-99.4M
$-193.9M
FCF Margin
GPRO
GPRO
RARE
RARE
Q4 25
7.4%
-48.6%
Q3 25
6.9%
-58.0%
Q2 25
5.4%
-66.5%
Q1 25
-43.5%
-120.5%
Q4 24
-12.7%
-48.3%
Q3 24
-1.6%
-49.2%
Q2 24
-0.1%
-53.7%
Q1 24
-63.9%
-178.2%
Capex Intensity
GPRO
GPRO
RARE
RARE
Q4 25
0.3%
0.5%
Q3 25
0.6%
0.8%
Q2 25
0.3%
1.5%
Q1 25
1.0%
1.0%
Q4 24
0.2%
0.1%
Q3 24
0.8%
1.2%
Q2 24
0.4%
1.4%
Q1 24
0.6%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GPRO
GPRO

Subscription And Services$106.3M53%
Other$95.4M47%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons